Skip to main content
Smart Investors Daily
Bristol-Myers Squibb Company logo

NYSE · BMY

Bristol-Myers Squibb Company

Healthcare · Drug Manufacturers - General

$59.56

Down-$1.22 (-2.05%)

Updated Nov 20, 2026, 1:45 AM

SID Score

6.0/10

Composite research score

Smart Money

58/100

Neutral

Market cap
104.23B
P/E ratio
17.28
Dividend yield
4.16%
52-week range
$53.44 – $68.64
Volume
11.11M
Avg. volume
16.54M

Price performance · BMY

BMY price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Nov 18, 2026

BMY closed at $59.56 after 20 trading sessions, down 5.46% for the selected period.

Last close
$59.56
Period change
-5.46%
Period low
$59.56
Period high
$64.19
Daily close
View OHLC price history
BMY OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 18, 2026$60.78$61.18$59.475$59.5611.11M
Nov 17, 2026$62.125$62.14$60.6442$61.3514.65M
Nov 16, 2026$64.94$64.94$62.82$62.9310M
Nov 13, 2026$62.56$63.785$61.813$63.439.27M
Nov 12, 2026$63.80$64.1211$62.31$62.329.39M
Nov 11, 2026$62.00$62.96$61.31$62.916.43M
Nov 10, 2026$61.67$62.915$61.30$62.807.62M
Nov 9, 2026$62.88$63.0641$61.80$62.147.67M
Nov 6, 2026$61.46$63.06$61.32$62.149.8M
Nov 5, 2026$65.00$65.54$62.985$63.139.03M
Nov 4, 2026$63.19$64.24$62.26$64.1914.13M
Nov 3, 2026$63.02$63.26$61.54$61.7110.29M
Nov 2, 2026$62.45$63.14$62.17$63.0210.84M
Oct 30, 2026$63.00$64.05$62.285$62.4812.67M
Oct 29, 2026$61.00$61.56$60.00$61.3914.77M
Oct 28, 2026$60.50$61.34$60.33$60.577.41M
Oct 27, 2026$61.21$61.64$60.92$61.557.78M
Oct 26, 2026$61.39$62.06$61.1145$61.617.84M
Oct 23, 2026$62.66$62.84$61.31$61.489.76M
Oct 22, 2026$61.46$63.59$61.04$63.0015.17M

Latest BMY news

The latest Smart Investors Daily articles mentioning BMY.

BMY research

Overview

Company profile and research snapshot.

Company profile

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Hold
Average target
$53.25
Implied upside
—
Analysts
17
BMY recent ratings
DateFirmRatingTarget
Oct 30, 2026Morgan StanleyUnderweight—
Oct 26, 2026Piper SandlerOverweight—
Oct 13, 2026Wells FargoEqual-Weight—
Oct 8, 2026Cantor FitzgeraldNeutral—
Oct 7, 2026Morgan StanleyUnderweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 13, 2026

2026 NewYorkCISO ORBIE Awards Recognize Greater New York’s Top Security Executives

Leading CISOs honored for leadership, enterprise security, and business impact at the NewYorkCISO ORBIE Awards on November 12, 2026, at the Ziegfeld Ballroom. NEW YORK, Nov. 13, 2026 (GLOBE NEWSWIRE) -- The 2026 NewYorkCISO ORBIE Awards honored leading chief information security officers (CISOs) from Bristol Myers Squibb, Crum & Forster, CVS Health, RWJBarnabas Health, J. Crew, Vista Equity Partners, and Ballistic Ventures for their exceptional leadership. Hosted by NewYorkCISO, a chapter of the

Yahoo · Nov 12, 2026

Bristol Myers Squibb (BMY) Stock Looks Below Fair Value Following A 41% Run

Bristol-Myers Squibb has quietly turned in a strong share price run over the past few years, helped by fresh data for key therapies and a solid pipeline story. With the stock around US$62.91 at the last close, the real question for you is whether that level is backed up by the cash the business can generate over time. Over the past 3 years the stock has returned about 40.5%, which puts real pressure on the cash flow outlook to justify the step up in market value. Recent trial results for...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.